-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, AeUJbz0akp2ogWvYOiTppO273+2J8GwMkDymKuJn7MfmKto8TN59WehNitZu2Yoh 4qi0DmfltJ28xCPRaQHa/A== 0000912282-10-000241.txt : 20100216 0000912282-10-000241.hdr.sgml : 20100215 20100216170701 ACCESSION NUMBER: 0000912282-10-000241 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20100216 DATE AS OF CHANGE: 20100216 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: ImmunoCellular Therapeutics, Ltd. CENTRAL INDEX KEY: 0000822411 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 931301885 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-59139 FILM NUMBER: 10609385 BUSINESS ADDRESS: STREET 1: 21900 BURBANK BLVD. STREET 2: 3RD FLOOR CITY: WOODLAND HILLS STATE: CA ZIP: 91367 BUSINESS PHONE: 818-992-2907 MAIL ADDRESS: STREET 1: 21900 BURBANK BLVD. STREET 2: 3RD FLOOR CITY: WOODLAND HILLS STATE: CA ZIP: 91367 FORMER COMPANY: FORMER CONFORMED NAME: Optical Molecular Imaging, Inc DATE OF NAME CHANGE: 20060202 FORMER COMPANY: FORMER CONFORMED NAME: PATCO INDUSTRIES LTD DATE OF NAME CHANGE: 19991025 FORMER COMPANY: FORMER CONFORMED NAME: REDWING VENTURES INC DATE OF NAME CHANGE: 19890705 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: RAB SPECIAL SITUATIONS (MASTER) FUND LTD CENTRAL INDEX KEY: 0001327372 IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: P.O. BOX 908 GT STREET 2: WALKER HOUSE MARY STREET CITY: GEORGE TOWN STATE: E9 ZIP: 0000 BUSINESS PHONE: 206-903-8850 MAIL ADDRESS: STREET 1: P.O. BOX 908 GT STREET 2: WALKER HOUSE MARY STREET CITY: GEORGE TOWN STATE: E9 ZIP: 0000 SC 13G/A 1 rabsc13ga_immunocell-123109.htm

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

 

SCHEDULE 13G

 

INFORMATION STATEMENT PURSUANT TO RULES 13d-1 AND 13d-2

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(AMENDMENT NO. 3)1

 

ImmunoCellular Therapeutics, Ltd.

(Name of Issuer)

 

 

 

Common Shares

(Title of Class of Securities)

 

 

 

452536105

(CUSIP Number)

 

 

December 31, 2009

(Date of Event Which Requires Filing of This Statement)

 

 

Check the Appropriate box to designate the rule pursuant to which this schedule is filed:

 

o

Rule 13d-1(b)

x

Rule 13d-1(c)

o

Rule 13d-1(d)

 

_________________________

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 



CUSIP No. 452536105

13G

Page 2 of 5 Pages

 

 

 

1

NAME OF REPORTING PERSONS

S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS

 

RAB Special Situations (Master) Fund Limited

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a) o
(b) o

3

SEC USE ONLY

 

 

4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Cayman Islands

 

5

SOLE VOTING POWER

NUMBER OF

 

452,100

SHARES

6

SHARED VOTING POWER

BENEFICIALLY

 

0

OWNED BY

7

SOLE DISPOSITIVE POWER

EACH

 

452,100

REPORTING

8

SHARED DISPOSITIVE POWER

PERSON WITH

 

0

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

452,100

10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*                        o

 

 

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

<5%

12

TYPE OF REPORTING PERSON*

 

CO



*SEE INSTRUCTIONS BEFORE FILLING OUT!

 



CUSIP No. 452536105

13G

Page 3 of 5 Pages

 

 

Item 1

(a).

Name of Issuer:

 

ImmunoCellular Therapeutics, Ltd.

 

Item 1

(b).

Address of Issuer’s Principal Executive Offices:

 

21900 Burbank Boulevard

Woodland Hills, California 91367

 

Item 2

(a).

Name of Person Filing:

 

RAB Special Situations (Master) Fund Limited

 

Item 2

(b).

Address of Principal Business Office or, if None, Residence:

 

RAB Special Situations (Master) Fund Limited

P. O. Box 908 GT

Walker House Mary Street

George Town, Cayman Islands

 

Item 2

(c).

Citizenship:

 

Cayman Islands

 

Item 2

(d).

Title of Class of Securities:

 

Common Shares

 

Item 2

(e).

CUSIP Number:

 

452536105

 

Item 3.

If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

 

 

(a)

o

Broker or dealer registered under Section 15 of the Act;

 

 

(b)

o

Bank as defined in Section 3(a)(6) of the Act;

 

 

(c)

o

Insurance Company as defined in Section 3(a)(19) of the Act;

 

 

(d)

o

Investment Company registered under Section 8 of the Investment Company Act;

 

 

(e)

o

Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

 

 

(f)

o

Employee benefit plan or endowment plan in accordance with Rule 13d-1(b)(1)(ii)(F);

 

 

(g)

o

Parent holding company or control person, in accordance with Rule 13d-1(b)(1)(ii)(G);

 

 

(h)

o

A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

 

 

(i)

o

A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940:

 

 

(j)

o

Group, in accordance with Rule 13d-1(b)(1)(ii)(j).

 

 

x

If this statement is filed pursuant to Rule 13d-1(c), check this box.


 



CUSIP No. 452536105

13G

Page 4 of 5 Pages

 

 

Item 4.

Ownership.

 

Provide the following information regarding the aggregate number and percentage of the class of securities identified in Item 1.

 

 

(a)

Amount beneficially owned:

 

See Item 9 on the cover page

 

 

(b)

Percent of class:

 

See Item 11 on the cover page

 

 

(c)

Number of shares as to which such person has:

 

 

(i)

Sole power to vote or to direct the vote

 

 

(ii)

Shared power to vote or to direct the vote

 

 

(iii)

Sole power to dispose or to direct the disposition of

 

 

(iv)

Shared power to dispose or to direct the disposition of

 

 

See Items 5-8 on the cover page

 

Instruction. For computations regarding securities which represent a right to acquire an underlying security, see Rule 13d-3(d)(1).

 

Item 5.

Ownership of Five Percent or Less of a Class.

 

If the statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following   x.

 

Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

 

N/A

 

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

 

N/A

 

Item 8.

Identification and Classification of Members of the Group.

 

N/A

 

Item 9.

Notice of Dissolution of Group.

 

N/A

 



CUSIP No. 452536105

13G

Page 5 of 5 Pages

 



Item 10.

Certification.

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

 

 

February 16, 2010

 

(Date)

 


RAB Special Situations (Master) Fund Limited
by Simon Gwyther and
Jake Leavesley

 

Authorised signatories for RAB Capital plc for
and on behalf of RAB Special Situations
(Master) Fund Limited

 

/s/ Simon Gwyther 

 

(Signature)

 

/s/ Jake Leavesley

(Signature)

 

 

 

-----END PRIVACY-ENHANCED MESSAGE-----